Provided by Tiger Trade Technology Pte. Ltd.

SIMCERE PHARMA

11.830
+0.8407.64%
Volume:14.74M
Turnover:171.07M
Market Cap:30.38B
PE:18.78
High:11.870
Open:11.520
Low:11.150
Close:10.990
52wk High:14.247
52wk Low:9.070
Shares:2.57B
HK Float Shares:2.57B
Volume Ratio:2.70
T/O Rate:0.57%
Dividend:0.21
Dividend Rate:1.77%
EPS(LYR):0.630
ROE:18.77%
ROA:7.78%
PB:2.76
PE(LYR):18.78
PS:2.98

Loading ...

Simcere Pharma buys back 1.38 million shares on 5 May; cumulative 2026 repurchases reach 15.05 million

Bulletin Express
·
May 05

Simcere Pharma Adds 847,000-Share Buyback; Cumulative Repurchases Reach 13.67 Million

Bulletin Express
·
May 04

SIMCERE PHARMA Spends HK$10 Million on Share Buyback

Stock News
·
May 04

Simcere files HKEX next-day disclosure return, reports share buyback at HKD 11.91

Reuters
·
May 04

SIMCERE PHARMA's New Drug Application for Ledokibai Monoclonal Antibody Accepted by Regulators

Stock News
·
Apr 30

Simcere says China regulator accepts NDA for atopic dermatitis drug rademikibart

Reuters
·
Apr 30

BRIEF-Simcere Pharmaceutical Says NDA For Rademikibart Accepted By NMPA

Reuters
·
Apr 30

Simcere Pharmaceutical - Nda for Rademikibart Accepted by Nmpa on April 29, 2026

THOMSON REUTERS
·
Apr 30

Simcere Pharmaceutical's Profit Jumps 86% in 2025

MT Newswires Live
·
Apr 29

先声药业2025年度业绩:营收同比增16.5%至77.31亿元 净利润大幅提升86.2%

Bulletin Express
·
Apr 28

Simcere Pharma’s 2025 ESG Report: 2.08 Billion RMB R&D Outlay, 22% Carbon-Intensity Cut and Strong Gender Parity

Bulletin Express
·
Apr 28

Simcere Pharmaceutical Publishes 2025 Annual Report and ESG Report, Implements Full Electronic Dissemination

Bulletin Express
·
Apr 28

Simcere Pharma Publishes 2025 Annual Report, Switches to Electronic Communication for Shareholders

Bulletin Express
·
Apr 28

Simcere Pharmaceutical publishes 2025 ESG report

Reuters
·
Apr 28

BRIEF-Simcere Pharma Withdraws NDA For Rademikibart, Expects To Resubmit Within April 2026

Reuters
·
Apr 22

SIMCERE PHARMA Withdraws and Plans to Resubmit New Drug Application for Ledokibart This Month

Stock News
·
Apr 22

Simcere Pharma to Resubmit NDA for Rademikibart; Phase 3 Data Show 96.6% EASI-75 at Week 52

Bulletin Express
·
Apr 22

Simcere Pharmaceutical - to Seek Regulatory Approval for Rademikibart Market Launch

THOMSON REUTERS
·
Apr 22

Simcere Pharmaceutical - Pharma Withdraws Nda for Rademikibart, Expects to Resubmit Within April 2026

THOMSON REUTERS
·
Apr 22

Simcere withdraws, plans to resubmit rademikibart atopic dermatitis NDA within month

Reuters
·
Apr 22